Adiponectin, a key adipokine in obesity related liver diseases

World Journal of Gastroenterology

Volumn 17, Issue 23, 2011, Pages 2801-2811

  Buechler, Christa ^a   Wanninger, Josef ^a   Neumeier, Markus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Adiponectin; Adipose tissue; Hepatic steatosis; Non alcoholic steatohepa titis; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ALANINE AMINOTRANSFERASE; ALDEHYDE OXIDASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CLOFIBRATE; CYTOCHROME P450 2E1; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PENTOXIFYLLINE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE; SQUALENE SYNTHASE; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA; VERY LOW DENSITY LIPOPROTEIN;

AEROBIC EXERCISE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT DISTRIBUTION; BODY MASS; DIET THERAPY; DYSLIPIDEMIA; ENZYME BINDING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INSULIN RESISTANCE; LIVER BIOPSY; LIVER INJURY; LIVER PROTECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSFERRIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 79959672175     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i23.2801     Document Type: Review

References (154)

1. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152
2. Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-974
3. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav 2008; 94: 206-218
4. Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007; 11: 1231-1249
5. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S57-S63
6. Schäffer A, Schölmerich J, Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue--emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastro-enterol Hepatol 2005; 2: 273-280
7. Messier V, Karelis AD, Robillard ME, Bellefeuille P, Brochu M, Lavoie JM, Rabasa-Lhoret R. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism 2010; 59: 20-24
8. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rit-tig K, Balletshofer B, Machicao F, Fritsche A, Häring HU. Identifcation and characterization of metabolically benign obesity in humans. Arch Intern Med 2008; 168: 1609-1616
9. Brochu M, Tchernof A, Dionne IJ, Sites CK, Eltabbakh GH, Sims EA, Poehlman ET. What are the physical characteristics associated with a normal metabolic profle despite a high level of obesity in postmenopausal women? J Clin En-docrinol Metab 2001; 86: 1020-1025
10. Brochu M, Mathieu ME, Karelis AD, Doucet E, Lavoie ME, Garrel D, Rabasa-Lhoret R. Contribution of the lean body mass to insulin resistance in postmenopausal women with visceral obesity: a Monet study. Obesity (Silver Spring) 2008; 16: 1085-1093
11. Catalán V, Gómez-Ambrosi J, Rodríguez A, Salvador J, Frühbeck G. Adipokines in the treatment of diabetes mel-litus and obesity. Expert Opin Pharmacother 2009; 10: 239-254
12. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K, Kitazawa R, Kitazawa S, Miyachi H, Maeda S, Egashira K, Kasuga M. MCP-1 contributes to macrophage infltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006; 116: 1494-1505
13. Zeyda M, Stulnig TM. Adipose tissue macrophages. Immunol Lett 2007; 112: 61-67
14. Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol 2008; 43: 811-822
15. Borst SE. The role of TNF-alpha in insulin resistance. Endocrine 2004; 23: 177-182
16. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic infammation in obese humans. Diabetes 2007; 56: 1010-1013
17. Sabio G, Das M, Mora A, Zhang Z, Jun JY, Ko HJ, Barrett T, Kim JK, Davis RJ. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 2008; 322: 1539-1543
18. Wiest R, Weigert J, Wanninger J, Neumeier M, Bauer S, Schmidhofer S, Farkas S, Scherer MN, Schäffer A, Schölm-erich J, Buechler C. Impaired hepatic removal of inter-leukin-6 in patients with liver cirrhosis. Cytokine 2011; 53: 178-183
19. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636
20. Biddinger SB, Miyazaki M, Boucher J, Ntambi JM, Kahn CR. Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes 2006; 55: 2032-2041
21. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, London RM, Brigstock D, George J. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723
22. Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fbrosis. Curr Opin Clin Nutr Metab Care 2009; 12: 404-411
23. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miya-gawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specifc protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83
24. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. Biochem J 2008; 409: 623-633
25. Neumeier M, Weigert J, Schäffer A, Wehrwein G, Müller-Ladner U, Schölmerich J, Wrede C, Buechler C. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol 2006; 79: 803-808
26. Schober F, Neumeier M, Weigert J, Wurm S, Wanninger J, Schäffler A, Dada A, Liebisch G, Schmitz G, Aslanidis C, Buechler C. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. Biochem Biophys Res Commun 2007; 361: 968-973
27. Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Ge G, Spooner E, Hug C, Gimeno R, Lodish HF. Identification and characterization of CTRP9, a novel secreted glycoprotein, from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin. FASEB J 2009; 23: 241-258
28. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010
29. Kusminski CM, McTernan PG, Schraw T, Kos K, ÓHare JP, Ahima R, Kumar S, Scherer PE. Adiponectin complexes in human cerebrospinal fluid: distinct complex distribution from serum. Diabetologia 2007; 50: 634-642
30. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adipo-nectin? Hepatology 2004; 40: 46-54
31. Neumeier M, Weigert J, Schäffler A, Weiss TS, Schmidl C, Büttner R, Bollheimer C, Aslanidis C, Schölmerich J, Buechler C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofbric acid in hepatocytes in vitro. Biochem Biophys Res Commun 2006; 350: 731-735
32. Targher G, Bertolini L, Scala L, Poli F, Zenari L, Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin Endocrinol (Oxf) 2004; 61: 700-703
33. Aguilar-Salinas CA, García EG, Robles L, Riaño D, Ruiz-Gomez DG, García-Ulloa AC, Melgarejo MA, Zamora M, Guillen-Pineda LE, Mehta R, Canizales-Quinteros S, Tusie Luna MT, Gómez-Pérez FJ. High adiponectin concentrations are associated with the metabolically healthy obese pheno-type. J Clin Endocrinol Metab 2008; 93: 4075-4079
34. Rubinstein E, Lavine JE, Schwimmer JB. Hepatic, cardiovascular, and endocrine outcomes of the histological sub-phenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 380-385
35. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link? J Hepatol 2008; 49: 300-302
36. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhorn JN, ÓDonnell CJ, Fox CS. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepa-tology 2010; 51: 1979-1987
37. Roberts EA. Non-alcoholic steatohepatitis in children. Clin Liver Dis 2007; 11: 155-172, x
38. Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adipo-nectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009; 53: 201-212
39. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic ste-atohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219
40. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967
41. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-S10
42. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology 1996; 24: 813-815
43. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: a clinical, morphological, and biochemical study. Int J Obes 1984; 8: 107-115
44. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231
45. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008; 115: 141-150
46. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009; 50 Suppl: S412-S416
47. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16: 421-427
48. Müssig K, Staiger H, Machicao F, Thamer C, Machann J, Schick F, Claussen CD, Stefan N, Fritsche A, Häring HU. RARRES2, encoding the novel adipokine chemerin, is a genetic determinant of disproportionate regional body fat distribution: a comparative magnetic resonance imaging study. Metabolism 2009; 58: 519-524
49. Loos RJ, Ruchat S, Rankinen T, Tremblay A, Pérusse L, Bouchard C. Adiponectin and adiponectin receptor gene variants in relation to resting metabolic rate, respiratory quotient, and adiposity-related phenotypes in the Quebec Family Study. Am J Clin Nutr 2007; 85: 26-34
50. Wang ZL, Xia B, Shrestha U, Jiang L, Ma CW, Chen Q, Chen H, Hu ZG. Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population. J Endocrinol Invest 2008; 31: 1086-1091
51. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Ma-nos MM, Terrault NA. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005; 41: 372-379
52. Mohanty SR, Troy TN, Huo D, ÓBrien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. J Hepatol 2009; 50: 797-804
53. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, Schork NJ, Shiehmorteza M, Yokoo T, Chavez A, Mid-dleton MS, Sirlin CB. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009; 136: 1585-1592
54. Wilfred de Alwis NM, Day CP. Genes and nonalcoholic fatty liver disease. Curr Diab Rep 2008; 8: 156-163
55. Wilfred de Alwis NM, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Semin Liver Dis 2007; 27: 44-54
56. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pen-nacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465
57. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010; 52: 894-903
58. Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI. Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology 2010; 139: 1567-1576, 1576.e1-e6
59. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathoge-netic role in NASH. Hepatology 2008; 47: 1167-1177
60. Kotronen A, Yki-Järvinen H, Aminoff A, Bergholm R, Pi-etiläinen KH, Westerbacka J, Talmud PJ, Humphries SE, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehren-borg E, Fisher RM. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur J Endocrinol 2009; 160: 593-602
61. Stefan N, Machicao F, Staiger H, Machann J, Schick F, Tschritter O, Spieth C, Weigert C, Fritsche A, Stumvoll M, Häring HU. Polymorphisms in the gene encoding adiponec-tin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 2005; 48: 2282-2291
62. Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, Hamilton MP, Luby-Phelps K, Scherer PE. Systemic fate of the adipo-cyte-derived factor adiponectin. Diabetes 2009; 58: 1961-1970
63. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008; 10: 156-164
64. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K. Adi-ponectin and adiponectin receptors in obesity-linked insulin resistance. Novartis Found Symp 2007; 286: 164-176; discussion 176-182, 200-203
65. Neumeier M, Hellerbrand C, Gäbele E, Buettner R, Boll-heimer C, Weigert J, Schäffer A, Weiss TS, Lichtenauer M, Schölmerich J, Buechler C. Adiponectin and its receptors in rodent models of fatty liver disease and liver cirrhosis. World J Gastroenterol 2006; 12: 5490-5494
66. Matsuzawa Y. The role of fat topology in the risk of disease. Int J Obes (Lond) 2008; 32 Suppl 7: S83-S92
67. Nakamura Y, Sekikawa A, Kadowaki T, Kadota A, Kad-owaki S, Maegawa H, Kita Y, Evans RW, Edmundowicz D, Curb JD, Ueshima H. Visceral and subcutaneous adiposity and adiponectin in middle-aged Japanese men: the ERA JUMP study. Obesity (Silver Spring) 2009; 17: 1269-1273
68. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46: 91-97
69. López-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernández-Real JM. Adiponectin, hepatocellu-lar dysfunction and insulin sensitivity. Clin Endocrinol (Oxf) 2004; 60: 256-263
70. Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol 2007; 102: 1931-1938
71. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, Xu A. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005; 280: 18341-18347
72. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, Igura T, Inui Y, Kihara S, Nakamura T, Yamashita S, Miyagawa J, Funahashi T, Matsuzawa Y. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm Metab Res 2000; 32: 47-50
73. Kobayashi K, Inoguchi T, Sonoda N, Sekiguchi N, Nawata H. Adiponectin inhibits the binding of low-density lipopro-tein to biglycan, a vascular proteoglycan. Biochem Biophys Res Commun 2005; 335: 66-70
74. Takemura Y, Ouchi N, Shibata R, Aprahamian T, Kirber MT, Summer RS, Kihara S, Walsh K. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007; 117: 375-386
75. Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, Gentilcore E, Natale S, Cassader M, Rizzetto M, Pasquali R, Marchesini G. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endo-crinol Metab 2005; 90: 3498-3504
76. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005; 152: 113-118
77. Vuppalanchi R, Marri S, Kolwankar D, Considine RV, Chalasani N. Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study. J Clin Gastroenterol 2005; 39: 237-242
78. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769
79. Neumeier M, Weigert J, Schäffler A, Weiss T, Kirchner S, Laberer S, Schölmerich J, Buechler C. Regulation of adiponec-tin receptor 1 in human hepatocytes by agonists of nuclear receptors. Biochem Biophys Res Commun 2005; 334: 924-929
80. Bauer S, Weigert J, Neumeier M, Wanninger J, Schäffer A, Luchner A, Schnitzbauer AA, Aslanidis C, Buechler C. Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals. Arch Med Res 2010; 41: 75-82
81. Weigert J, Neumeier M, Wanninger J, Wurm S, Kopp A, Schober F, Filarsky M, Schäffler A, Zeitoun M, Aslanidis C, Buechler C. Reduced response to adiponectin and lower abundance of adiponectin receptor proteins in type 2 diabetic monocytes. FEBS Lett 2008; 582: 1777-1782
82. Inukai K, Nakashima Y, Watanabe M, Takata N, Sawa T, Kurihara S, Awata T, Katayama S. Regulation of adiponec-tin receptor gene expression in diabetic mice. Am J Physiol Endocrinol Metab 2005; 288: E876-E882
83. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S, Kamon J, Kobayashi M, Suzuki R, Hara K, Kubota N, Terau-chi Y, Froguel P, Nakae J, Kasuga M, Accili D, Tobe K, Ueki K, Nagai R, Kadowaki T. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 2004; 279: 30817-30822
84. Nannipieri M, Cecchetti F, Anselmino M, Mancini E, Mar-chetti G, Bonotti A, Baldi S, Solito B, Giannetti M, Pinchera A, Santini F, Ferrannini E. Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic ste-atohepatitis. Obes Surg 2009; 19: 467-474
85. Ma H, Gomez V, Lu L, Yang X, Wu X, Xiao SY. Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2009; 24: 233-237
86. Uribe M, Zamora-Valdés D, Moreno-Portillo M, Bermejo-Martínez L, Pichardo-Bahena R, Baptista-González HA, Ponciano-Rodríguez G, Uribe MH, Medina-Santillán R, Méndez-Sánchez N. Hepatic expression of ghrelin and adi-ponectin and their receptors in patients with nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 67-71
87. Shimizu A, Takamura T, Matsuzawa N, Nakamura S, Nabemoto S, Takeshita Y, Misu H, Kurita S, Sakurai M, Yo-koyama M, Zen Y, Sasaki M, Nakanuma Y, Kaneko S. Regulation of adiponectin receptor expression in human liver and a hepatocyte cell line. Metabolism 2007; 56: 1478-1485
88. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-121
89. Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofbrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res 2009; 50: 2193-2202
90. Koh IU, Lim JH, Joe MK, Kim WH, Jung MH, Yoon JB, Song J. AdipoR2 is transcriptionally regulated by ER stress-inducible ATF3 in HepG2 human hepatocyte cells. FEBS J 2010; 277: 2304-2317
91. Tietge UJ, Böker KH, Manns MP, Bahr MJ. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemody-namics. Am J Physiol Endocrinol Metab 2004; 287: E82-E89
92. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13: 3540-3553
93. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147: 173-180
94. Zietz B, Herfarth H, Paul G, Ehling A, Müller-Ladner U, Schölmerich J, Schäffer A. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Lett 2003; 545: 103-104
95. Awazawa M, Ueki K, Inabe K, Yamauchi T, Kaneko K, Okazaki Y, Bardeesy N, Ohnishi S, Nagai R, Kadowaki T. Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1/LKB1/AMPK dependent pathway. Biochem Bio-phys Res Commun 2009; 382: 51-56
96. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003; 112: 91-100
97. Qiao L, Zou C, van der Westhuyzen DR, Shao J. Adiponec-tin reduces plasma triglyceride by increasing VLDL triglyc-eride catabolism. Diabetes 2008; 57: 1824-1833
98. Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans 2002; 30: 1064-1070
99. Yamauchi T, Kadowaki T. Physiological and pathophysi-ological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond) 2008; 32 Suppl 7: S13-S18
100. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-ac-tivated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular infammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-257
101. Al-Attas OS, Al-Daghri NM, Al-Rubeaan K, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009; 8: 20
102. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci USA 1997; 94: 2557-2562
103. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Mascianà R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887
104. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fbrosis progression in nonalcoholic steatohepatitis. J Hepatol 2009; 51: 371-379
105. Matsumoto H, Tamura S, Kamada Y, Kiso S, Fukushima J, Wada A, Maeda N, Kihara S, Funahashi T, Matsuzawa Y, Shimomura I, Hayashi N. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine-induced liver injury in mice. World J Gastroenterol 2006; 12: 3352-3358
106. Ouchi N, Walsh K. Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007; 380: 24-30
107. Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adipo-nectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol 2008; 28: 1368-1374
108. Tsao TS, Murrey HE, Hug C, Lee DH, Lodish HF. Oligo-merization state-dependent activation of NF-kappa B signaling pathway by adipocyte complement-related protein of 30 kDa (Acrp30). J Biol Chem 2002; 277: 29359-29362
109. Park PH, McMullen MR, Huang H, Thakur V, Nagy LE. Short-term treatment of RAW264.7 macrophages with adi-ponectin increases tumor necrosis factor-alpha (TNF-alpha) expression via ERK1/2 activation and Egr-1 expression: role of TNF-alpha in adiponectin-stimulated interleukin-10 production. J Biol Chem 2007; 282: 21695-21703
110. Saijo S, Nagata K, Nakano Y, Tobe T, Kobayashi Y. Inhibition by adiponectin of IL-8 production by human macro-phages upon coculturing with late apoptotic cells. Biochem Biophys Res Commun 2005; 334: 1180-1183
111. Tsatsanis C, Zacharioudaki V, Androulidaki A, Dermitzaki E, Charalampopoulos I, Minas V, Gravanis A, Margioris AN. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-infammatory stimuli. Biochem Biophys Res Commun 2005; 335: 1254-1263
112. Weigert J, Obermeier F, Neumeier M, Wanninger J, Filar-sky M, Bauer S, Aslanidis C, Rogler G, Ott C, Schäffler A, Schölmerich J, Buechler C. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn's disease. Infamm Bowel Dis 2010; 16: 630-637
113. Abke S, Neumeier M, Weigert J, Wehrwein G, Eggenhofer E, Schäffer A, Maier K, Aslanidis C, Schölmerich J, Buechler C. Adiponectin-induced secretion of interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1, CCL2) and inter-leukin-8 (IL-8, CXCL8) is impaired in monocytes from patients with type I diabetes. Cardiovasc Diabetol 2006; 5: 17
114. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T, Kouroumalis EA. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Infamm Bowel Dis 2006; 12: 100-105
115. Rovin BH, Song H. Chemokine induction by the adipocyte-derived cytokine adiponectin. Clin Immunol 2006; 120: 99-105
116. Fantuzzi G. Adiponectin and infammation: consensus and controversy. J Allergy Clin Immunol 2008; 121: 326-330
117. Luedde T, Beraza N, Kotsikoris V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steato-hepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11: 119-132
118. Wanninger J, Neumeier M, Weigert J, Bauer S, Weiss TS, Schäffer A, Krempl C, Bleyl C, Aslanidis C, Schölmerich J, Buechler C. Adiponectin-stimulated CXCL8 release in primary human hepatocytes is regulated by ERK1/ERK2, p38 MAPK, NF-kappaB, and STAT3 signaling pathways. Am J Physiol Gastrointest Liver Physiol 2009; 297: G611-G618
119. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621
120. Hanson JC, Bostick MK, Campe CB, Kodali P, Lee G, Yan J, Maher JJ. Transgenic overexpression of interleukin-8 in mouse liver protects against galactosamine/endotoxin tox-icity. J Hepatol 2006; 44: 359-367
121. Jung TW, Lee YJ, Lee MW, Kim SM, Jung TW. Full-length adiponectin protects hepatocytes from palmitate-induced apoptosis via inhibition of c-Jun NH2 terminal kinase. FEBS J 2009; 276: 2278-2284
122. Wedemeyer I, Bechmann LP, Odenthal M, Jochum C, Mar-quitan G, Drebber U, Gerken G, Gieseler RK, Dienes HP, Canbay A. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. J Hepatol 2009; 50: 140-149
123. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shima-bukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J 2006; 70: 1437-1442
124. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, Fukui K, Maeda N, Nishizawa H, Nagaretani H, Oka-moto Y, Kihara S, Miyagawa J, Shinomura Y, Funahashi T, Matsuzawa Y. Enhanced carbon tetrachloride-induced liver fbrosis in mice lacking adiponectin. Gastroenterology 2003; 125: 1796-1807
125. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000; 105: 1067-1075
126. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-1653
127. Garattini E, Fratelli M, Terao M. Mammalian aldehyde oxi-dases: genetics, evolution and biochemistry. Cell Mol Life Sci 2008; 65: 1019-1048
128. Kundu TK, Hille R, Velayutham M, Zweier JL. Characterization of superoxide production from aldehyde oxidase: an important source of oxidants in biological tissues. Arch Biochem Biophys 2007; 460: 113-121
129. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339
130. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fbrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99
131. Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepa-titis in mice. Hepatology 2008; 48: 458-473
132. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol 2005; 166: 1655-1669
133. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepa-tology 2008; 47: 677-685
134. Handy JA, Saxena NK, Fu P, Lin S, Mells JE, Gupta NA, Anania FA. Adiponectin activation of AMPK disrupts leptin-mediated hepatic fbrosis via suppressors of cytokine signaling (SOCS-3). J Cell Biochem 2010; 110: 1195-1207
135. Jardé T, Caldefe-Chézet F, Goncalves-Mendes N, Mishel-lany F, Buechler C, Penault-Llorca F, Vasson MP. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009; 16: 1197-1210
136. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725
137. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intra-hepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009; 17: 2162-2168
138. Johnson NA, Sachinwalla T, Walton DW, Smith K, Armstrong A, Thompson MW, George J. Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology 2009; 50: 1105-1112
139. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepa-titis. Hepatology 2010; 51: 121-129
140. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413
141. Pasarica M, Tchoukalova YD, Heilbronn LK, Fang X, Albu JB, Kelley DE, Smith SR, Ravussin E. Differential effect of weight loss on adipocyte size subfractions in patients with type 2 diabetes. Obesity (Silver Spring) 2009; 17: 1976-1978
142. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clo-fbrate in the treatment of non-alcohol-induced steatohepa-titis: a pilot study. Hepatology 1996; 23: 1464-1467
143. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafka AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22: 873-883
144. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosigli-tazone. Hepatology 2003; 38: 1008-1017
145. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Spon-seller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferas-es, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. J Hepatol 2003; 38: 434-440
146. Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006; 27: 715-723
147. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Mat-suzawa Y. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099
148. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, Cusi K. Pioglitazone in the treatment of NASH: the role of adiponectin. Aliment Pharmacol Ther 2010; 32: 769-775
149. Gastaldelli A, Harrison SA, Belfort-Aguilar R, Hardies LJ, Balas B, Schenker S, Cusi K. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 2009; 50: 1087-1093
150. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-infammatory properties. Cell Metab 2007; 6: 137-143
151. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Benefcial effects of pentoxifylline on hepatic steatosis, fbro-sis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 634-638
152. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, Cheng CL, Wee A, Lim SG. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steato-hepatitis (NASH). Hepatol Int 2008; 2: 196-201
153. Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study. Intern Med J 2007; 37: 229-235
154. Ristow M, Zarse K, Oberbach A, Klöting N, Birringer M, Kiehntopf M, Stumvoll M, Kahn CR, Blüher M. Antioxi-dants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci USA 2009; 106: 8665-8670